NIH Translational Research Consortium Mulls How Best To Leverage Agency's Stake In Industry, Academia, Government Relationships
This article was originally published in The Pink Sheet Daily
Executive Summary
"We all have different carrots and different challenges, but we also have a great deal in common, including the goal to provide improved treatments and preventions for the public," says NCRR Director Alving.
You may also be interested in...
FDA, NIH Devise Regulatory Research Agenda, Look For Financing
The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translational Science Awards program.
FDA, NIH Devise Regulatory Research Agenda, Look For Financing
The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Science Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translation Science Awards program.
NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says
The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.